The Relationship between Admission HbA1c Level and Infarct-Related Artery Patency in ST Elevation Myocardial Infarction Patients

Objective: Patency of infarct-related artery (IRA) in patients with ST segment elevation myocardial infarction (STEMI) before pri-mary percutaneous coronary intervention (pPCI) is associated with lower mortality and better clinical outcome. This study aimed to investigate the relationship between admission hemoglobin A1c (HbA1c) and IRA patency before mechanical reperfusion in patients with STEMI.Methods: A total of 140 consecutive patients with STEMI undergoing pPCI within 12 h from symptom onset were retrospectively evaluated. The IRA patency was assessed by the thrombolysis in myocardial infarction (TIMI) flow grade. Patients were initially di-vided into two groups based on the TIMI flow grade. Impaired flow was defined as TIMI grades 0 and 1, and normal flow or patency was defined as TIMI 2 and 3. Patients were divided into three groups based on admission HbA1c levels as group I (HbA1c ≤ 5.6%), group II (HbA1c 5.6%–6.5%), and group III (HbA1c ≥ 6.5%).Results: Among 140 patients, 46 (32.8%) had pre-pPCI TIMI 2 and 3 flow in IRA. The IRA patency was found to be similar in all three HbA1c groups (p=0.269). Admission HbA1c levels were similar in both IRA groups (p=0.314). In multivariate regression analysis, only MPV (OR:0.589, 95%CI:0.365–0.951, p=0.030) was significantly and independently associated with IRA patency.Conclusion: HbA1c is not an independent predictor of the IRA patency in patients with STEMI treated with pPCI. However, MPV is a simple, low-cost, and easily accessible parameter and might be used as a predictor of IRA patency.

PDF

___

1. Onat A, Can G, Yüksel H, Ademoğlu E, Erginel-Ünaltuna N, Kaya A, et al. Tıp dünyasının kronik hastalıklara yaklaşımına öncülük. Onat A, editör TEKHARF: Erişkinlerimizde kalp hastalıkları prevalansı, yeni koroner olaylar ve kalpten ölüm sıklığı, İstanbul: Logos yayıncılık 2017: 20-7.
2. Ezzati M, Obermeyer Z, Tzoulaki I, Mayosi BM, Elliott P, Leon DA. Con-tributions of risk factors and medical care to cardiovascular mortali-ty trends. Nat Rev Cardiol 2015; 12: 508-30.[CrossRef ]
3. Barchielli A, Santoro GM, Balzi D, Carrabba N, Di Bari M, Gensini GF, et al. Long-term prognosis after primary PCI in unselected patients with ST-elevation myocardial infarction. J Cardiovasc Med 2012; 13: 819-27. [CrossRef ]
4. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myo-cardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39: 119-77. [CrossRef ]
5. Szuszkiewicz-Garcia MM, Davidson JA. Cardiovascular disease in di-abetes mellitus: risk factors and medical therapy. Endocrinol Metab Clin North Am 2014; 43: 25-40.[CrossRef ]
6. Brown A, Reynolds LR, Bruemmer D. Intensive glycemic control and cardiovascular disease: an update.Nat Rev Cardiol 2010; 7: 369-75.
7. Shan PF, Li Q, Khamaisi M, Qiang GF. Type 2 Diabetes Mellitus and Macro-vascular Complications. Int J Endocrinol 2017; 2017: 4301461.[CrossRef ]
8. Rensing KL, Reuwer AQ, Arsenault BJ, von der Thüsen JH, Hoekstra JB, Kastelein JJ, et al. Reducing cardiovascular disease risk in pa-tients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing? Diabetes Obes Metab 2011; 13: 1073-87. [CrossRef ]
9. Cao JJ, Hudson M, Jankowski M, Whitehouse F, Weaver WD. Relation of chronic and acute glycemic control on mortality in acute myocar-dial infarction with diabetes mellitus. Am J Cardiol 2005; 96: 183-86. [CrossRef ]
10. Hadjadj S, Coisne D, Mauco G, Ragot S, Duengler F, Sosner P, et al. Prognostic value of admission plasma glucose and HbA1c in acute myocardial infarction. Diabet Med 2004; 21: 305-10. [CrossRef ]
11. Berry C, Noble S, Gregoire J, Ibrahim R, Levesquie S, Lavoie MA, et al. Glycaemic status influences the nature and severity of coronary artery disease. Diabetologia 2010; 53: 652-8. [CrossRef ]
12. Gibson CM. Has my patient achieved adequate myocardial reperfu-sion? Circulation 2003; 108: 504-7.[CrossRef ]
13. Nammas W, Pietila M, Romppanen H, Sia J, DeBelder A, Karjalainen PP. Outcomes of poor initial TIMI flow in patients presenting with acute coronary syndrome. Scand Cardiovasc J 2017; 51: 248-54. [CrossRef ]
14. Westerhout CM, Bonnefoy E, Welsh RC, Steg PG, Boutitie F, Arm-strong PW. The influence of time from symptom onset and reper-fusion strategy on 1-year survival in ST-elevation myocardial in-farction: a pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST. Am Heart J 2011; 161: 283-90. [CrossRef ]
15. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment eleva-tion myocardial infarction: a meta-analysis. JAMA 2004; 292: 362-6.[CrossRef ]
16. De Luca G, Gibson CM, Gyöngyösi M, Zeymer U, Dudek D, Arntz HR, et al. Gender-related differences in outcome after ST-segment el-evation myocardial infarction treated by primary angioplasty and glycoprotein IIb–IIIa inhibitors: insights from the EGYPT coopera-tion. J Thromb Thrombol 2010; 30: 342-6. [CrossRef ]
17. Doğan M, Akyel A, Bilgin M, Erat M, Çimen T, Sunman H, et al. Can admission neutrophil to lymphocyte ratio predict infarct-related artery patency in ST-segment elevation myocardial infarction. Clin Appl Thromb Hemost 2015; 21: 172-6. [CrossRef ]
18. Şahin DY, Gür M, Elbasan Z, Yıldız A, Kaya Z, İçen YK, et al. Predictors of preinterventional patency of infarct-related artery in patients with ST-segment elevation myocardial infarction: Importance of neutrophil to lymphocyte ratio and uric acid level. Exp Clin Cardiol 2013; 18: e77.
19. Elbasan Z, Gür M, Şahin DY, Kuloglu O, Icen YK, Turkoglu C, et al. As-sociation of mean platelet volume and pre-and postinterventional flow with infarct-related artery in ST-segment elevation myocardial infarction. Angiology 2013; 64: 440-6.[CrossRef ]
20. Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33: 62. [CrossRef ]
21. Members ATF, Steg PG, James SK, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. ESC Guidelines for the management of acute myo-cardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33: 2569-619. [CrossRef ]
22. Bailleul C, Puymirat E, Aissaoui N, Schiele F, Ducrocq G, Coste P, et al. Factors associated with infarct-related artery patency before prima-ry percutaneous coronary intervention for st-elevation myocardial infarction (from the FAST-MI 2010 registry). Am J Cardiol 2016; 117: 17-21.[CrossRef ]
23. Brener SJ, Mehran R, Brodie BR, Guagliumi G, Witzenbichler B, Cris-tea E, et al. Predictors and Implications of Coronary Infarct Artery Pate ncy at Initial Angiography in Patients With Acute Myocardial Infarction (from the CADILLAC and HORIZONS-AMI Trials). Am J Car-diol 2011; 108: 918-23. [CrossRef ]
24. Mehta RH, Harjai KJ, Cox D, Stone GW, Brodie B, Boura J, et al. Clinical and angiographic correlates and outcomes of suboptimal coronary flow in patients with acute myocardial infarction undergoing prima-ry percutaneous coronary intervention. J Am Coll Cardiol 2003; 42: 1739-46.[CrossRef ]
25. Rakowski T, Dudek D, van ‘t Hof A, Ten Berg J, Soulat L, Zeymer U, et al. Impact of acute infarct-related artery patency before percuta-neous coronary intervention on 30-day outcomes in patients with ST-segment elevation myocardial infarction treated with prima-ry percutaneous coronary intervention in the EUROMAX trial. Eur Heart J Acute Cardiovasc Care 2018; 7: 514-21.[CrossRef ]
26. Rakowski T, Dudek D, Dziewierz A, Yu J, Witzenbichler B, Guagliumi G, et al. Impact of infarct-related artery patency before primary PCI on outcome in patients with ST-segment elevation myocardial in-farction: the HORIZONS-AMI trial. Euro Intervention 2013; 8: 1307-14. [CrossRef ]
27. Wu J, Pride YB, Frederick PD, Gibson CM. Association of initial throm-bolysis in myocardial infarction flow grade with mortality among patients with ST-segment elevation myocardial infarction undergo-ing primary percutaneous coronary intervention: a National Regis-try of Myocardial Infarction-5 (NRMI-5) analysis. Am Heart J 2011; 162: 178-83.[CrossRef ]
28. Valgimigli M, Campo G, Malagutti P, Anselmi M, Bolognese L, Rib-ichini F, et al. Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the strategy (single high-dose bolus tirofiban and siro-limus-eluting stent versus abciximab and bare-metal stent in acute myocardial infarction) and multistrategy (multicenter evaluation of single high-dose bolus tirofiban versus abciximab with sirolim-us-eluting stent or bare-metal stent in acute myocardial infarction study) trials. JACC 2011; 4: 51-62.
29. Yao H, Ekou A, Hadeou A, N’Djessan JJ, Kouamé I, N’Guetta R. Medi-um and long-term follow-up after ST segment elevation myocardial infarction in a sub-Saharan Africa population:a prospective cohort study. BMC Cardiovasc Disord 2019; 19: 65-71. [CrossRef ]
30. Tenerz Å, Nilsson G, Forberg R, Ohrvik J, Malmberg K, Berne C, et al. Basal glucometabolic status has an impact on long‐term prognosis following an acute myocardial infarction in non‐diabetic patients. J Intern Med 2003; 254: 494-503. [CrossRef ]
31. Tian L, Zhu J, Liu L, Liang Y, Li J, Yang Y. Hemoglobin A1c and short-term outcomes in patients with acute myocardial infarction under-going primary angioplasty: an observational multicenter study. Coron Artery Dis 2013; 24: 16-22.[CrossRef ]
32. Cicek G, Uyarel H, Ergelen M, Ayhan E, Abanonu GB, Eren M, et al. Hemoglobin A1c as a prognostic marker in patients undergoing pri-mary angioplasty for acute myocardial infarction. Coron Artery Dis 2011; 22: 131-7. [CrossRef ]
33. Timmer JR, Hoekstra M, Nijsten MW, van der Horst IC, Ottervanger JP, Slingerland RJ, et al. Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with ST-segment–elevation myocardial infarction treated with percutaneous coro-nary intervention. Circulation 2011; 124: 704-11. [CrossRef ]
34. Pusuroglu H, Akgul O, Cakmak HA, Erturk M, Surgit O, Celik O, et al. Long-term prognostic value of admission haemoglobin A1c (HbA1c) levels in patients with ST-segment elevation myocardial in-farction undergoing primary percutaneous coronary intervention. Postepy Kardiol Interwencyjnej 2014; 10: 166. [CrossRef ]
35. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Associ-ation of hemoglobin A1c with cardiovascular disease and mortali-ty in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2014; 141: 413-20. [CrossRef ]
36. Lee CH, Lee SW, Park SW. Diabetes and subclinical coronary athero-sclerosis. Diabetes Metab J 2018; 42: 355-63. [CrossRef ]
37. Gerstein H, Islam S, Anand S, Almahmeed W, Damasceno A, Dans A, et al. Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study. Diabetologia 2010; 53: 2509-17. [CrossRef ]
38. Lee CH, Teo SG, Hong E, Wong HB, Low A, Sutandar A, et al. Impact of glycemic control on occurrence of no-reflow and 30-day outcomes in diabetic patients undergoing primary angioplasty for myocardial infarction. J Invasive Cardiol 2005; 17: 422-6.
39. Eskesen K, Jensen M, Galatius S, Vestergaard H, Hildebrandt P, Ma-rott JL, et al. Glycated haemoglobin and the risk of cardiovascular disease, diabetes and all‐cause mortality in the Copenhagen City Heart Study. J Intern Med 2013; 273: 94-101. [CrossRef ]
40. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010; 362: 800-11. [CrossRef ]
41. Wolf D, Ley K. Immunity and Inflammation in Atherosclerosis. Circ Res 2019; 124: 315-27. [CrossRef ]
42. Fuentes Q E, Fuentes Q F, Andrés V, Pello OM, Font de Mora J, Palomo GI. Role of platelets as mediators that link inflammation and throm-bosis in atherosclerosis. Platelets 2013; 24: 255-62.[CrossRef ]
43. Maseri A, Fuster V. Is there a vulnerable plaque? Circulation 2003; 107: 2068-71.[CrossRef ]
44. Brener SJ, Mehran R, Brodie BR, Guagliumi G, Witzenbichler B, Cris-tea E, et al. Predictors and implications of coronary infarct artery patency at initial angiography in patients with acute myocardial infarction (from the CADILLAC and HORIZONS-AMI Trials). Am J Car-diol 2011; 108: 918-23. [CrossRef ]
45. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Hackeng CM, ten Berg JM. The relationship between platelet reactivity and infarct-re-lated artery patency in patients presenting with a ST-elevation myo-cardial infarction. Thromb Haemost 2011; 105: 331-6. [CrossRef ]
46. Celik T, Kaya MG, Akpek M, Gunebakmaz O, Balta S, Sarli B, et al. Pre-dictive value of admission platelet volume indices for in-hospital major adverse cardiovascular events in acute ST-segment elevation myocardial infarction. Angiology 2015; 66: 155-62. [CrossRef ]
47. Sen F, Yilmaz S, Balci KG, Gül M, Balcı MM, Akboga MK, et al. The relationship between epicardial adipose tissue thickness and in-farct-related artery patency in patients with ST-segment elevation myocardial infarction. Angiology 2016; 67: 281-6. [CrossRef ]
48. Yayla Ç, Akboğa MK, Canpolat U, Akyel A, Yayla KG, Doğan M, et al. Platelet to lymphocyte ratio can be a predictor of infarct-related artery patency in patients with ST-segment elevation myocardial infarction. Angiology 2015; 66: 831-6. [CrossRef ]
49. Akboga MK, Yayla C, Yilmaz S, Sen F, Balcı KG, Ozcan F, et al. Increased red cell distribution width predicts occlusion of the infarct-related artery in STEMI. Scand Cardiovasc J 2016; 50: 114-8.[CrossRef ]
50. Huczek Z, Kochman J, Filipak KJ, Horszczaruk GJ, Grabowski M, Pi-atkowski R , et al. Mean platelet volüme on admission predicts im-paired reperfusion and long-term mortality in acute myocardial in-farction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2005; 46: 284-90.[CrossRef ]
51. Kurtul A, Açıkgöz SK. Usefulness of mean platelet volume to lym-phocyte ratio for predicting angiographic no-reflow and short term prognosis after primary percutaneous coronary intervention in pa-tients with ST-segment elevation myocardial infarction. Am J Cardi-ol 2017; 120: 534-41. [CrossRef ]
52. Kurtul A, Yarlıoglues M, Murat SN, Ergun G, Duran M, Kasapkara HA, et al. Usefulness of platelet to lymphocyte ratio in predicting angio-graphic reflow after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. Am J Cardiol 2014; 114: 342-7.[CrossRef ]